Vascular targeting and the inhibition of angiogenesis.
Recent advances in our understanding of the process by which tumours elicit an angiogenic response, and of differences between normal and tumour vasculature, are revealing new strategies for anticancer therapy. The current status of anti-angiogenic therapy, together with approaches to targeting tumour vasculature, is reviewed. In particular, the advantages of using tumour vasculature as a target for anticancer gene therapy are outlined.
Bicknell
R
R
Imperial Cancer Research Fund, John Radcliffe Hospital, Oxford, U.K.
D043925:Angiogenesis Inducing Agents / Q000037:antagonists & inhibitors / Q000502:physiology; D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D003510:Cyclohexanes; D004730:Endothelium, Vascular / Q000187:drug effects; D005231:Fatty Acids, Unsaturated / Q000494:pharmacology; D015316:Genetic Therapy; D006801:Humans; D008970:Molecular Weight; D009369:Neoplasms / Q000098:blood supply* / Q000188:drug therapy / Q000628:therapy; D009389:Neovascularization, Pathologic / Q000473:pathology / Q000517:prevention & control*; D010426:Pentosan Sulfuric Polyester / Q000494:pharmacology; D010978:Platelet Factor 4 / Q000494:pharmacology; D011135:Polysaccharides, Bacterial / Q000494:pharmacology; D011506:Proteins / Q000494:pharmacology; D012717:Sesquiterpenes; D013498:Suramin / Q000494:pharmacology
D043925:Angiogenesis Inducing Agents; D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D003510:Cyclohexanes; D005231:Fatty Acids, Unsaturated; D011135:Polysaccharides, Bacterial; D011506:Proteins; D012717:Sesquiterpenes; C079061:tecogalan; D010978:Platelet Factor 4; D010426:Pentosan Sulfuric Polyester; D013498:Suramin; C026211:fumagillin